13 results about "Retinal progenitor" patented technology

The present invention provides methods of constructing vascularized retinal organoids by differentiating retinal progenitor cells and endothelial cells. The method is co-cultured by differentiating retinal progenitor cells and endothelial cells, and comprises the following steps: carrying out multiplication culture on pluripotent stem cells until the cell confluence degree is 80-90%, and digesting; carrying out differentiation culture on the digested pluripotent stem cells in a culture medium containing retina induction factors to obtain retina progenitor cells; and co-culturing the retinal progenitor cells differentiated for 12-13 days and endothelial cells to obtain the vascularized retinal organ, wherein the endothelial cells are obtained by any one method of induced differentiation of digested pluripotent stem cells or culture of endothelial cell lines. The vascularized retinal organ with the retinal layered structure is constructed by integrating the endothelial cells and the retinal progenitor cells for the first time, and the limitation that in the prior art, the retinal organ lacks vascularization is successfully overcome.

The disclosure pertains to a defined cell culture medium for the expansion of human retinal progenitors, comprising or consisting of a nutrient medium, a SHH-pathway activator and a GSK3 inhibitor. To the use of the defined cell culture medium for the expansion of retinal progenitors, as well as to an in vitro method for expanding retinal progenitors, comprising: (i) placing a culture of human retinal progenitors in a defined cell culture medium as defined in claims 1 to 8; and (ii) culturing the cells in said defined cell culture medium.

The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.

The present invention relates to retinal progenitor cells simultaneously exhibiting characteristics of retinal pigment epithelial cells, photoreceptor cells, and lens epithelial cells, and a mass production method therefor. When retinal progenitor cells are isolated and cultured using the method according to one aspect, the retinal progenitor cells can be mass-produced in a short time, and thus the method is economical. In addition, the isolated retinal progenitor cells exhibit all of the differentiation characteristics of retinal pigment epithelial cells, photoreceptor cells and lens epithelial cells. Therefore, the present invention can be effectively used in the fields of research on retinal diseases such as macular degeneration, and research and development of therapeutic agents.

The disclosure pertains to a defined cell culture medium for the expansion of human retinal progenitors, comprising or consisting of a nutrient medium, a SHH-pathway activator and a GSK3 inhibitor. To the use of the defined cell culture medium for the expansion of retinal progenitors, as well as to an in vitro method for expanding retinal progenitors, comprising: (i) placing a culture of human retinal progenitors in a defined cell culture medium as defined in claims 1 to 8; and (ii) culturing the cells in said defined cell culture medium.

The present invention provides a method for maintaining a continuous epithelial structure of a retinal tissue including culturing the retinal tissue in a medium comprising a methyl group donor or a substrate of the methyl group donor at a concentration at which cell differentiation of a neural retinal progenitor cell is suppressed, and a neurite extension inhibitor at a concentration at which neurite extension is suppressed.

Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells.

The present invention relates generally to a method of producing an induced retinal progenitor cell, an induced RPCs, and to a treatment using such a cell, and to a method of producing an induced RPCs, an induced retinal progenitor cell, an induced RPCs, and to a treatment using such a cell.

Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells. The subject matter described herein also provides cell populations comprising retinal progenitor cells and methods of isolation thereof.

The invention provides a method for simultaneously differentiating endothelial cells and pericytes and co-culturing with retinal progenitor cells to construct a vascularized retinal organ. The method comprises the following steps: carrying out multiplication culture on pluripotent stem cells until the cell confluence degree is 80-90%, and digesting; carrying out differentiation culture on the digested pluripotent stem cells in a retinal organ-containing differentiation culture medium to obtain retinal progenitor cells; carrying out differentiation culture on the digested pluripotent stem cells in a blood vessel lineage cell sphere-containing differentiation culture medium to obtain a blood vessel lineage cell mixed population; and co-culturing the retinal progenitor cells differentiated for 12-13 days and the blood vessel pedigree cell mixed group differentiated for 8-9 days to obtain the vascularized retinal organ. The vascular network in the vascularized retina-like organ provided by the invention not only comprises endothelial cells, but also comprises pericytes, and also comprises a plurality of retina nerve cells, and has complex retina structures and functions.

The invention relates to the technical field of medicines, in particular to a delivery preparation containing isorhamnetin and CRISPR Cas9 plasmids as well as a preparation method and application of the delivery preparation. According to the isorhamnetin delivery preparation, the polylactic acid-glycolic acid copolymer is used as an inner shell material of the delivery preparation, a hydrophobic drug isorhamnetin is wrapped, a fat-soluble drug isorhamnetin is prepared into a hydrophilic preparation, and the problem that isorhamnetin is difficult to prepare into a medicine is solved; polyethyleneimine is used as a middle layer material of the delivery preparation, CRISPR Cas9 plasmid is loaded, efficient gene loading is achieved, ACSL4 gene is specifically knocked out, and ferroptosis is inhibited; 2, 3-dimethyl maleic anhydride functionalized poly-L-lysine is used as a middle layer material of the delivery preparation, and the charge reversal characteristic is introduced; by using the hypoxic retinal precursor cell membrane as the shell material of the delivery preparation, the delivery preparation has good biocompatibility and retina targeting effect.

The present invention relates to methods for obtaining a retinal progenitor cell and related products from stem cells. The present invention also relates to retinal progenitor cells that may be produced by said method and the uses of said retinal progenitor cells, such as further differentiation of said retinal progenitor cells into retinal pigment epithelium (RPE) cells and retinal organoids. The invention also relates to a suspension cell culture comprising a retinal progenitor cell or a cluster thereof obtained by the method. The invention also relates to a suspension cell culture comprising a retinal progenitor cell or a cluster thereof obtained by the method. In addition, the invention refers to CD133 as marker for identification / enrichment / isolation of photoreceptor cells.

In alternative embodiments, provided herein are methods for isolating primary retinal cells obtained or isolated from a human sample. In alternative embodiments, provided are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells or regenerating a macular and / or a scotopic visual function.